Age-related Macular Degeneration: Genetic and Environmental Factors of Disease
Table 2
Pharmacogenetic Studies of Treatment Outcome in AMD
| Intervention | Gene/locus | Variants | Results |
|---|---|---|---|
| Photodynamic therapy | CFH | rs1061170 (Y402H) | Controversial: Outcome for CC genotype lagged CT and TT (83); outcome for TT was poorer (82); no genotype association (84, 85). |
| LOC387715 | rs10490924 (A69S) | No significant genotype association (86). | |
| VEGF | rs699947, rs2146323 | Anatomic outcome was strongly linked to SNPs (87). | |
| CRP | rs2808635, rs876538 | Positive response was significantly associated with both variants (85). | |
| HTRA1 | rs11200638 | No significant association (86). | |
| FV | G1691A | Better outcome associated in patients carrying both genetic variants (88, 89). | |
| FII | G20210A | ||
| MTHFR | C677T | Better outcome associated with variant (88–90). | |
| FXIIIA | G185T | Poorer outcome associated with variant (88–89). | |
| Intravitreal bevacizumab | CFH | rs1061170 (Y402H) | CC genotype responded significantly worse than TC and TT (94); CC genotype more likely to require re-injection (95). |
| LOC387715 | rs10490924 (A69S) | No significant association (94). | |
| Antioxidants and zinc | CFH | rs1061170 (Y402H) | TT genotype responds better than CC (98). |
| LOC387715 | rs10490924 (A69S) | No significant association (98). | |
